

2019 年中国临床肿瘤学年度进展研讨会 (BOC)

暨 Best of ASCO® 2019 China

大会组织机构:

大会主席团成员: (以姓氏拼音排序)

程颖、樊嘉、郭军、赫捷、江泽飞、李进、李萍萍、梁军、梁后杰、马军、秦叔逵、吴一龙、王绿化、徐瑞华、于金明、朱军

大会主席: 李进、秦叔逵、马军

大会秘书长: 江泽飞

会议日程

会议第一天 2019 年 7 月 5 日 (Day 1, July 5, 2019)

8:00-8:15 开幕式

主持人: CSCO 秘书长 江泽飞

开幕致辞: CSCO 理事长 李进

胃肠肿瘤专场 1 (Gastrointestinal Cancer Session 1)

主席(Chair): 李进 沈琳

时间(Time)	题目(Topic)	讲者(Speaker)
8:15-8:25	Abstract 4017 S-1 plus oxaliplatin versus S-1 plus cisplatin as first-line treatment for advanced diffuse-type or mixed-type gastric/gastroesophageal junction adenocarcinoma: A randomized, phase 3 trial.	徐瑞华
8:25-8:40	Efficacy and safety of PD-1 blockade with JS001 in patients with advanced neuroendocrine neoplasms: a non-randomized, open-label, phase 1b trial 比较紫杉醇联合卡培他滨方案和顺铂联合卡培他滨方案对于进展期胃癌的疗效和安全性的多中心、随机对照III期临床研究	陆明

8:40-8:55	专家评述 Expert Review	刘天舒
8:55-9:05	讨论(Q & A)	
胃肠肿瘤专场 2 (Gastrointestinal Cancer Session 2) 主席(Chairman): 徐瑞华 张苏展		
时间(Time)	题目(Topic)	讲者(Speaker)
9:05-9:20	Abstract ID: 3501 Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).	陈 功
	Abstract ID: 3504 FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer.	
9:20-9:40	FRESCO 研究: 呋喹替尼对比安慰剂在经治的转移性结直肠癌患者中对总生存的影响	李进
	西妥昔单抗联合 FOLFOX4 方案对比 FOLFOX4 方案一线治疗 RAS 野生型转移性结直肠癌的前瞻性随机对照研究	
9:40-9:50	AXEPT 研究: mXELIRI 对比 FOLFIRI 联合或不联合贝伐珠单抗用于 mCRC 二线治疗的一项多中心、开放标签、随机、非劣效、III期研究	陈晓锋
9:50-10:05	专家评述 Expert Review	张苏展
10:05-10:15	讨论(Q & A)	
血液系统恶性肿瘤专场 (Hematologic Malignancies Session) 主席(Chair): 马 军 朱 军 胡建达		
时间(Time)	题目(Topic)	讲者(Speaker)
10:15-10:40	Abstract ID: 7510 Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib.	赵东陆
	Abstract ID: 7507 Rituximab maintenance for patients with diffuse large B-cell lymphoma in first complete remission: Results from a randomized HOVON-Nordic Lymphoma Group phase III study.	

	Abstract ID: 8001 E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma.	
10:40-10:50	吉西他滨, 奥沙利铂联合利妥昔单抗一线治疗老年弥漫大 B 细胞淋巴瘤: 一项单臂, 开放, 2 期研究	应志涛
10:50-11:05	专家评述 Expert Review	贡铁军
11:05-11:15	讨论(Q & A)	
肝胆胰肿瘤专场 (Hepatobiliary/Pancreatic Cancer Session)		
主席(Chair): 秦叔逵 樊嘉 梁军		
时间(Time)	题目(Topic)	讲者(Speaker)
11:15-11:40	Abstract ID: LBA4 Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.	刘秀峰
	Abstract ID: 4000 APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant <i>nab</i> -paclitaxel plus gemcitabine (<i>nab</i> -P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.	
	A Randomized Multicentered Phase 2 Study to Evaluate SHR-1210 (PD-1 Antibody) in Subjects with Advanced Hepatocellular Carcinoma (HCC) who Failed or Intolerable to Prior Systemic Treatment.	
11:40-11:50	肝动脉灌注奥沙利铂联合氟尿嘧啶 (FOLFOX) 化疗 vs 索拉非尼治疗进展期肝细胞癌	杨田
11:50-12:05	专家评述 Expert Review	梁后杰
12:05-12:15	讨论(Q & A)	
12:30-13:45	午餐和/或卫星会(Lunch and/or Satellite Symposium)	
乳腺癌专场 1 (Breast Cancer Session 1)		
主席(Chair): 耿翠芝 王晓稼		

时间(Time)	题目(Topic)	讲者(Speaker)
14:00-14:25	Abstract ID: 1000 SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).	殷咏梅
	Abstract ID: 1002 Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.	
	Abstract ID: 1001 Pyrotinib combined with capecitabine in women with HER2+ metastatic breast cancer previously treated with trastuzumab and taxanes: A randomized phase III study.	
14:25-14:40	专家评述 Expert Review	王树森
14:40-14:50	讨论(Q & A)	
乳腺癌专场 2 (Breast Cancer Session2) 主席(Chair): 于金明 王海波		
时间(Time)	题目(Topic)	讲者(Speaker)
14:50-15:15	Abstract ID: 1003 IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).	郝春芳
	Abstract ID: 503 Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx.	
	Phase III trial of chidamide, a subtype-selective histone deacetylase (HDAC) inhibitor, in combination with exemestane in patients with hormone receptor-positive advanced breast cancer	
15:15-15:30	专家评述 Expert Review	刘 健
15:30-15:40	讨论(Q & A)	

妇科肿瘤专场 (Gynecologic Cancer Session)		
主席(Chair): 吴令英 杨宏英		
时间(Time)	题目(Topic)	讲者(Speaker)
15:40-16:05	Abstract ID: 5505 Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer. A randomized controlled chemotherapy-free study—NSGO-AVANOVA2/ENGOT-OV24.	李 宁
	Abstract ID: 5506 Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial.	
	Abstract ID: 5508 EWOC-1: A randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): A GCIG-ENGOT-GINECO study.	
16:05-16:20	专家评述 Expert Review	李 力
16:20-16:30	讨论(Q & A)	

会议第二天 2019年7月6日 (Day 2, July 6, 2019)

肺癌专场 1 (Lung Cancer Session 1)		
主席(Chair): 赫捷 程颖		
时间(Time)	题目(Topic)	讲者(Speaker)
08:15-08:30	Abstract ID: 8506 Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial.	胡 毅
	Abstract ID: 9016 Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC.	

08:30-08:50	安罗替尼作为三线及以上治疗进展期非小细胞肺癌的生存分析： ALTER 3 期随机临床试验	杨 帆
	厄洛替尼对比长春瑞滨+顺铂用于中国 EGFR 突变阳性 IIIA 期非小细胞肺癌辅助治疗 (EVAN)：一项随机，开放，2 期临床研究	
08:50-09:05	专家评述 Expert Review	范 云
09:05-09:15	讨论(Q & A)	

肺癌专场 2 (Lung Cancer Session 2)

主席(Chair): 周彩存 王绿化 王 洁

时间(Time)	题目(Topic)	讲者(Speaker)
9:15-9:30	Phase 2 study of tepotinib + gefitinib (TEP+GEF) in MET-positive (MET+)/epidermal growth factor receptor (EGFR)-mutant (MT) non-small cell lung cancer (NSCLC)	钟文昭
	CTONG 1103 Erlotinib versus Gemcitabine plus Cisplatin as Neoadjuvant Treatment for Stage IIIA-N2 EGFR-mutation Non-small-cell lung cancer (EMERGING): a Randomised Study	
9:30-9:40	Primary results of ALESIA: A randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naïve ALK+ advanced NSCLC	任胜祥
9:40-09:55	专家评述 Expert Review	周彩存
09:55-10:05	讨论(Q & A)	

泌尿系统（前列腺）肿瘤专场 Genitourinary (Prostate) Cancer Session

主席: 周芳坚 马建辉

时间(Time)	题目(Topic)	讲者(Speaker)
10:05-10:30	Abstract ID: LBA2 Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.	周爱萍
	Abstract ID: 5006 First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts)	

	with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).	
	Abstract ID: 5007 Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: An interim safety analysis.	
10:30-10:40	索拉菲尼联合吉西他滨、顺铂治疗转移性肾集合管癌：一项多中心前瞻性单臂二期临床研究	盛锡楠
10:40-10:55	专家评述 Expert Review	何志嵩
10:55-11:05	讨论(Q & A)	
头颈肿瘤专场 (Head and Neck Cancer)		
主席：唐平章 胡超苏		
时间(Time)	题目(Topic)	讲者(Speaker)
11:05-11:30	Abstract ID: 6000 Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).	李志铭
	Abstract ID: 6002 TPExtreme randomized trial: TPEX versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).	
	Abstract ID: 6003 Gemcitabine and cisplatin (GP) induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) versus CCRT alone in locoregionally advanced nasopharyngeal carcinoma (NPC): A phase 3, multicenter, randomized controlled trial.	
11:30-11:45	专家评述 Expert Review	郭 晔
11:45-11:55	讨论 (Q & A)	
12:30-13:45	午餐和/或卫星会(Lunch and/or Satellite Symposium)	
免疫治疗专场 (Immunotherapy Session)		
主席(Chair)：郭 军 王宝成		

14:00-14:25	Abstract ID: 9501 Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).	斯 璐
	Abstract ID: 4500 Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.	
	Abstract ID: 8503 Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).	
14:25-14:40	专家评述 Expert Review	朱 波
14:40-14:50	讨论(Q & A)	
Current Standard Practice after ASCO 2019 主席(Chair): 秦叔逵 赫 捷 程 颖		
时间(Time)	题目(Topic)	讲者(Speaker)
14:55-15:20	Current Standard Practice after ASCO 2019: Gastrointestinal Cancer	李 进
	Q & A (5 mins)	
15:20-15:45	Current Standard Practice after ASCO 2019: Hepatobiliary/Pancreatic Cancer	秦叔逵
	Q & A (5 mins)	
15:45-16:10	Current Standard Practice after ASCO 2019: Lymphoma	宋玉琴
	Q & A (5 mins)	
16:10-16:35	Current Standard Practice after ASCO 2019: Breast Cancer	江泽飞
	Q & A (5 mins)	
16:35-17:00	Current Standard Practice after ASCO 2019: Lung Cancer	

	Q & A (5 mins)	程颖
17:00-17:15	大会闭幕致辞 秦叔逵教授	